Ulcerative Colitis - Pipeline Review, H2 2012

Ulcerative Colitis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Ulcerative Colitis - Pipeline Review, H2 2012', provides an overview of the Ulcerative Colitis therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcerative Colitis. 'Ulcerative Colitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ulcerative Colitis.
- A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ulcerative Colitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Ulcerative Colitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Ulcerative Colitis Therapeutic Products under Development, Key Players in Ulcerative Colitis Therapeutics, Ulcerative Colitis Pipeline Overview, Ulcerative Colitis Pipeline, Ulcerative Colitis Pipeline Assessment SHOW LESS READ MORE >

2
List of Tables 6
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Ulcerative Colitis Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Ulcerative Colitis 11
Ulcerative Colitis Therapeutics under Development by Companies 13
Ulcerative Colitis Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Ulcerative Colitis Therapeutics – Products under Development by Companies 24
Ulcerative Colitis Therapeutics – Products under Investigation by Universities/Institutes 29
Companies Involved in Ulcerative Colitis Therapeutics Development 30
Bristol-Myers Squibb Company 30
Johnson & Johnson 31
Abbott Laboratories 32
Biogen Idec Inc. 33
Amgen Inc. 34
Athersys, Inc. 35
GlaxoSmithKline plc 36
Genentech, Inc. 37
MedImmune LLC 38
Euroscreen S.A. 39
Takeda Pharmaceutical Company Limited 40
BioLineRx, Ltd. 41
Celltrion, Inc. 42
Sylentis 43
Novartis AG 44
Pfizer Inc. 45
Zeria Pharmaceutical Co Ltd 46
4SC AG 47
Hollis-Eden Pharmaceuticals, Inc. 48
Karo Bio 49
Ore Pharmaceuticals Inc 50
Cosmo Pharmaceuticals S.p.A 51
Lexicon Pharmaceuticals, Inc. 52
Pluristem Therapeutics Inc. 53
Proximagen Neuroscience plc. 54
InDex Pharmaceuticals AB 55
Am-Pharma B.V. 56
Palau Pharma S.A 57
7TM Pharma A/S 58
Hutchison MediPharma Limited 59
Tillotts Pharma AG 60
Coronado Biosciences, Inc. 61
Txcell SA 62
Atlantic Pharmaceuticals, Inc. 63
China Medical System Holdings Limited 64
Drais Pharmaceuticals, Inc. 65
Giuliani S.p.A. 66
KYORIN Pharmaceutical Co., Ltd. 67
Synergy Pharmaceuticals, Inc. 68
NasVax Ltd. 69
Dr. Falk Pharma GmbH 70
Transcription Factor Therapeutics, Inc. 71
Altheus Therapeutics, Inc. 72
AesRx, LLC. 73
LIPID THERAPEUTICS GmbH 74
Sigmoid Pharma. 75
Ulcerative Colitis – Therapeutics Assessment 76
Assessment by Monotherapy Products 76
Assessment by Combination Products 77
Assessment by Route of Administration 78
Assessment by Molecule Type 81
Drug Profiles 84
Lialda - Drug Profile 84
RG7413 - Drug Profile 86
ASP3291 - Drug Profile 88
Tofacitinib - Drug Profile 89
Alicaforsen - Drug Profile 91
Anti-IL-13 Mab - Drug Profile 92
BMS-936557 - Drug Profile 93
MultiStem - Drug Profile 94
GSK1399686 - Drug Profile 96
LX1032 - Drug Profile 98
AEB071 - Drug Profile 100
HMPL-004 - Drug Profile 102
Triolex - Drug Profile 104
Kappaproct - Drug Profile 106
Dersalazine Sodium - Drug Profile 108
MLN0002 - Drug Profile 110
MLN0002 - Drug Profile 112
Budesonide MMX - Drug Profile 114
Humira - Drug Profile 116
Avonex - Drug Profile 118
4SC-101 - Drug Profile 119
ORE1001 - Drug Profile 121
UC1-TX - Drug Profile 123
OvaSave - Drug Profile 124
Remicade - Drug Profile 125
IMA-638 - Drug Profile 127
LT-02 - Drug Profile 129
KRP-203 - Drug Profile 130
Z-206 - Drug Profile 132
PAR-2 Program - Drug Profile 133
GSK2245840 - Drug Profile 134
Budesonide - Drug Profile 137
Cannabidiol - Drug Profile 139
LMW Heparin MMX - Drug Profile 140
PUR0110 - Drug Profile 141
TSO - Drug Profile 142
Avrina - Drug Profile 144
5-ASA - Drug Profile 145
5-ASA + Tacrolimus - Drug Profile 146
Simponi - Drug Profile 147
Adalimumab - Drug Profile 149
Polyphenon E - Drug Profile 150
AMG 181 - Drug Profile 151
Dex 21-P-Encapsulated Erythrocytes - Drug Profile 152
CyCol - Drug Profile 153
Cimzia - Drug Profile 154
Oral Recombinant Alkaline Phosphatase - Drug Profile 155
Zoenasa - Drug Profile 156
Cannabis - Drug Profile 157
Umbilical Cord Mesenchymal Stem Cells - Drug Profile 158
Natura-Alpha - Drug Profile 160
Drug For Chron's Disease And Ulcerative Colitis - Drug Profile 162
Profermin - Drug Profile 163
ROR-gamma Program - Drug Profile 164
SP-333 - Drug Profile 165
PLX–IBD - Drug Profile 166
EryDex - Drug Profile 167
CMS-H002 - Drug Profile 169
AJM300 - Drug Profile 170
Anti-aCD3 Mab - Drug Profile 172
OKT3 + Omeprazole - Drug Profile 174
Leukothera - Drug Profile 175
BL-7040 - Drug Profile 176
Methotrexate - Drug Profile 178
ESN-282 - Drug Profile 179
ONS-1220 - Drug Profile 180
GS071 - Drug Profile 181
ONS- 3010 - Drug Profile 182
ONS-3020 - Drug Profile 183
Oral Zoenasa - Drug Profile 184
TP-02 - Drug Profile 185
Ulcerative Colitis Therapeutics – Drug Profile Updates 186
Ulcerative Colitis Therapeutics – Discontinued Products 219
Ulcerative Colitis Therapeutics - Dormant Products 221
Ulcerative Colitis – Product Development Milestones 226
Featured News & Press Releases 226
Appendix 235
Methodology 235
Coverage 235
Secondary Research 235
Primary Research 235
Expert Panel Validation 235
Contact Us 236
Disclaimer 236

List of Tables
Number of Products Under Development for Ulcerative Colitis, H2 2012 16
Products under Development for Ulcerative Colitis – Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 19
Number of Products under Development by Companies, H2 2012 (Contd..1) 20
Number of Products under Development by Companies, H2 2012 (Contd..2) 21
Number of Products under Development by Companies, H2 2012 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H2 2012 24
Comparative Analysis by Late Stage Development, H2 2012 25
Comparative Analysis by Mid Clinical Stage Development, H2 2012 26
Comparative Analysis by Early Clinical Stage Development, H2 2012 27
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 28
Products under Development by Companies, H2 2012 29
Products under Development by Companies, H2 2012 (Contd..1) 30
Products under Development by Companies, H2 2012 (Contd..2) 31
Products under Development by Companies, H2 2012 (Contd..3) 32
Products under Development by Companies, H2 2012 (Contd..4) 33
Products under Investigation by Universities/Institutes, H2 2012 34
Bristol-Myers Squibb Company, H2 2012 35
Johnson & Johnson, H2 2012 36
Abbott Laboratories, H2 2012 37
Biogen Idec Inc., H2 2012 38
Amgen Inc., H2 2012 39
Athersys, Inc., H2 2012 40
GlaxoSmithKline plc, H2 2012 41
Genentech, Inc., H2 2012 42
MedImmune LLC, H2 2012 43
Euroscreen S.A., H2 2012 44
Takeda Pharmaceutical Company Limited, H2 2012 45
BioLineRx, Ltd., H2 2012 46
Celltrion, Inc., H2 2012 47
Sylentis, H2 2012 48
Novartis AG, H2 2012 49
Pfizer Inc., H2 2012 50
Zeria Pharmaceutical Co Ltd, H2 2012 51
4SC AG, H2 2012 52
Hollis-Eden Pharmaceuticals, Inc., H2 2012 53
Karo Bio, H2 2012 54
Ore Pharmaceuticals Inc, H2 2012 55
Cosmo Pharmaceuticals S.p.A, H2 2012 56
Lexicon Pharmaceuticals, Inc., H2 2012 57
Pluristem Therapeutics Inc., H2 2012 58
Proximagen Neuroscience plc., H2 2012 59
InDex Pharmaceuticals AB, H2 2012 60
Am-Pharma B.V., H2 2012 61
Palau Pharma S.A, H2 2012 62
7TM Pharma A/S, H2 2012 63
Hutchison MediPharma Limited, H2 2012 64
Tillotts Pharma AG, H2 2012 65
Coronado Biosciences, Inc., H2 2012 66
Txcell SA, H2 2012 67
Atlantic Pharmaceuticals, Inc., H2 2012 68
China Medical System Holdings Limited, H2 2012 69
Drais Pharmaceuticals, Inc., H2 2012 70
Giuliani S.p.A., H2 2012 71
KYORIN Pharmaceutical Co., Ltd., H2 2012 72
Synergy Pharmaceuticals, Inc., H2 2012 73
NasVax Ltd., H2 2012 74
Dr. Falk Pharma GmbH, H2 2012 75
Transcription Factor Therapeutics, Inc., H2 2012 76
Altheus Therapeutics, Inc., H2 2012 77
AesRx, LLC., H2 2012 78
LIPID THERAPEUTICS GmbH, H2 2012 79
Sigmoid Pharma., H2 2012 80
Assessment by Monotherapy Products, H2 2012 81
Assessment by Combination Products, H2 2012 82
Assessment by Stage and Route of Administration, H2 2012 85
Assessment by Stage and Molecule Type, H2 2012 88
Ulcerative Colitis Therapeutics – Drug Profile Updates 191
Ulcerative Colitis Therapeutics – Discontinued Products 224
Ulcerative Colitis Therapeutics – Discontinued Products (Contd..1) 225
Ulcerative Colitis Therapeutics – Dormant Products 226
Ulcerative Colitis Therapeutics – Dormant Products (Contd..1) 227
Ulcerative Colitis Therapeutics – Dormant Products (Contd..2) 228
Ulcerative Colitis Therapeutics – Dormant Products (Contd..3) 229
Ulcerative Colitis Therapeutics – Dormant Products (Contd..4) 230

List of Figures
Number of Products under Development for Ulcerative Colitis, H2 2012 16
Products under Development for Ulcerative Colitis – Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 23
Late Stage Products, H2 2012 25
Mid Clinical Stage Products, H2 2012 26
Early Clinical Stage Products, H2 2012 27
Discovery and Pre-Clinical Stage Products, H2 2012 28
Assessment by Monotherapy Products, H2 2012 81
Assessment by Combination Products, H2 2012 82
Assessment by Route of Administration, H2 2012 83
Assessment by Stage and Route of Administration, H2 2012 84
Assessment by Molecule Type, H2 2012 86
Assessment by Stage and Molecule Type, H2 2012 87